We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Home CompaniesXilio Development Inc

Xilio Development Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
8.1 USD -0.37 ( 4.37%)
Last update at 2026-11-12T15:40:00Z
VOLUME
2605
Market Cap
59.42M

Momentum Score

…

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.10
Low
8.25
High
52 Week Price Range
6.47
Low
12.74
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
8.47
Dividend Yield
-
Revenue TTM
64.09M
Revenue Per Share
9.74
Gross Profit TTM
53.30M
Debt / Equity
0.20
ROE
-55.03%
Net Debt
-130.58M
ROCE
-35.60%
Diluted EPS TTM
-0.32

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -35.04M -58.24M -76.40M -88.22M -75.80M
Net income -35.04M -58.24M -76.40M -87.30M -74.30M
Selling general administrative 29.71M 24.78M 27.00M 29.95M 23.86M
Selling and marketing expenses - - 1.90M - -
Gross profit 42.23M 6.34M -1.90M - -
Reconciled depreciation 1.54M 1.64M 1.94M 1.85M 1.50M
Ebit -35.04M -59.65M -76.40M -91.00M -76.54M
Ebitda -33.49M -58.00M -74.50M -89.15M -75.04M
Depreciation and amortization 1.54M 1.64M 1.90M 1.85M 1.50M
Non operating income net other - - - 0.93M -0.76M
Operating income -41.98M -60.58M -79.13M -89.15M -75.04M
Other operating expenses 85.75M 66.93M 79.13M 89.15M 75.04M
Interest expense - 0.10M 0.13M -0.93M 0.76M
Income tax expense - - -0.93M -0.93M -1.50M
Total revenue 43.77M 6.34M 0.00M 0.00M 0.00M
Total operating expenses 84.21M 66.93M 79.13M 89.15M 75.04M
Cost of revenue 1.54M 1.64M 1.90M - -
Total other income expense net 6.95M 2.34M 2.73M 0.93M -0.76M
Net income from continuing ops -35.04M -58.24M -81.22M -88.22M -75.80M
Net income applicable to common shares - - - -88.22M -75.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 154.69M 71.08M 60.93M 139.16M 218.06M
Other current assets 2.50M 4.94M 3.42M 4.11M 4.46M
Total liab 119.41M 53.48M 24.10M 33.52M 32.63M
Total stockholder equity 35.27M 17.60M 36.83M 105.65M 185.43M
Other current liab 11.74M 9.98M 10.50M 10.41M 0.08M
Common stock 36.89M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.01M - 0.00M 0.00M
Retained earnings -418.79M -383.75M -325.51M -249.11M -160.89M
Other liab - - - - 32.63M
Other assets - - - 1.61M 231.66M
Cash 137.53M 55.29M 44.70M 120.39M 198.05M
Total current liabilities 56.27M 27.26M 15.96M 21.12M 12.78M
Current deferred revenue 40.02M 13.52M - - 8.75M
Net debt -130.58M -47.15M -32.15M -100.45M -177.52M
Short term debt 1.34M 1.19M 4.41M 7.58M 0.80M
Short long term debt - - - 6.67M -
Short long term debt total 6.95M 8.14M 12.55M 19.94M 20.54M
Other stockholder equity 417.17M 401.35M 362.34M 354.75M 346.31M
Property plant equipment - - - 7.25M 13.60M
Total current assets 145.03M 60.23M 48.13M 124.50M 202.52M
Net tangible assets - - - 105.65M 185.43M
Net receivables 5.00M - - 0.27M 0.39M
Long term debt - - - 3.17M 9.63M
Accounts payable 3.17M 2.57M 1.05M 3.12M 3.14M
Accumulated other comprehensive income - - - - -218.06M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -249.11M -160.89M
Non currrent assets other 1.81M 1.78M 0.01M 1.83M 1.95M
Non current assets total 9.66M 10.84M 12.80M 14.67M 15.54M
Capital lease obligations 6.95M 8.14M - 10.11M 10.91M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.04M -0.99M -1.87M -1.10M
Change to liabilities - - - 2.07M -8.44M
Total cashflows from investing activities -0.52M -0.04M -0.49M -1.87M -1.10M
Net borrowings 0.00M -3.38M -6.75M -0.09M -0.03M
Total cash from financing activities 87.78M 29.20M -6.55M -0.07M 260.67M
Change to operating activities - - - 1.52M -8.98M
Net income -35.04M -58.24M -76.40M -88.22M -75.80M
Change in cash 82.27M 10.78M -75.68M -77.66M 178.82M
Begin period cash flow 57.07M 46.29M 120.39M 199.61M 20.79M
End period cash flow 139.34M 57.07M 44.70M 121.95M 199.61M
Total cash from operating activities -4.99M -18.38M -68.62M -75.72M -80.75M
Issuance of capital stock 40.66M 6.83M 0.00M 0.00M 261.25M
Depreciation 1.54M 1.64M 1.90M 1.85M 1.50M
Change to account receivables -5.00M - - - -
Sale purchase of stock 2.81M - 0.19M 0.02M 261.53M
Other cashflows from financing activities 87.78M 25.75M 0.20M 0.02M 145.39M
Change to netincome - - - 8.65M 5.15M
Capital expenditures 0.52M 0.04M 0.49M 1.87M 1.10M
Cash flows other operating - - - -0.07M -3.17M
Cash and cash equivalents changes - - - -77.66M 178.82M
Change in working capital 25.12M 31.78M -1.66M 2.00M -11.80M
Stock based compensation 6.94M 6.43M 7.38M 8.42M 4.96M
Other non cash items -3.56M 0.00M 0.16M 0.22M 0.17M
Free cash flow -5.51M -18.41M -69.11M -77.59M -81.85M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
XLO
Xilio Development Inc		 -0.37
4.37%		 8.10 - - 0.93 0.81 10.21 -0.11
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Xilio Development Inc

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

828 Winter Street, Waltham, MA, United States, 02451

857 524 2466

https://xiliotx.com

76

Name Title Year Born
Dr. Rene Russo BCPS, Pharm.D, Pharm.D. CEO & Director 1975
Dr. Martin H. Huber M.D. Pres and Head of R&D 1961
Dr. Uli Bialucha Ph.D. Chief Scientific Officer NA
Mr. Christopher Frankenfield Chief Legal & Admin. Officer NA
Julissa Viana VP of Corp. Communications NA
Mr. Bill Avery Ph.D. Sr. VP of Nonclinical Devel. NA
Ms. Stacey J. Davis Chief Bus. Officer NA
Dr. Rene Russo BCPS, Pharm.D. President, CEO & Director 1975
Mr. Kevin M. Brennan Senior VP of Finance & Accounting 1970
Mr. Christopher Frankenfield Chief Operating Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PARA
USD 0.10
+38.58%
LUNR
USD 13.91
+14.20%
MBGL
USD 22.63
+13.60%
FRMI
USD 2.04
+12.71%
FIGR
USD 26.97
+11.49%
CDNL
USD 6.09
-59.37%
ADIG
USD 11.79
-39.79%
CTVA
USD 9.21
-24.11%
BZ
USD 12.99
-22.28%
ENVX
USD 1.98
-21.70%

Equity Sectors*

  • Basic Materials

    -1.40%

  • Communication Services

    -0.45%

  • Consumer Cyclical

    -0.55%

  • Consumer Defensive

    -0.01%

  • Energy

    -0.01%

  • Financial Services

    -0.40%

  • Financials

    -0.15%

  • Healthcare

    -1.15%

  • Industrials

    -0.46%

  • Real Estate

    -0.29%

  • Technology

    -1.22%

  • Utilities

    -0.10%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…